Clinical Trial Update: Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies [Phase 1]

View source ↗

Summary

A Phase I study to evaluate SYS6055 injection in participants with relapsed/refractory B-cell malignancies is not yet recruiting. The study is sponsored by the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• SYS6055

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory B-Cell Malignancies | Phase 1 | Status: NOT_YET_RECRUITING